* Eli Lilly and Co is expected to show a rise in quarterly revenue when it reports results on April 30 for the period ending March 31 2024
* The Indianapolis Indiana-based company is expected to report a 28.2% increase in revenue to $8.922 billion from $6.96 billion a year ago, according to the mean estimate from 16 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Eli Lilly and Co is for earnings of $2.46 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 5.5% in the last three months.
* Wall Street's median 12-month price target for Eli Lilly and Co is $837.50, above its last closing price of $724.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 2.22 2.22 2.49 Beat 12.2
Sep. 30 2023 -0.09 -0.13 0.10 Beat 174.3
Jun. 30 2023 1.97 1.98 2.11 Beat 6.6
Mar. 31 2023 1.69 1.73 1.62 Missed -6.2
Dec. 1.76 1.78 2.09 Beat 17.4
31 2022
Sep. 30 2022 1.89 1.92 1.98 Beat 3.3
Jun. 30 2022 1.72 1.69 1.25 Missed -26
Mar. 31 2022 2.39 2.32 2.77 Beat 19.2
This summary was machine generated April 26 at 13:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
